



Nektar Therapeutics Class Action Lawsuit - NKTR

Nektar Therapeutics
NASDAQ: NKTR

Affected NKTR Investor Summary

- **Who:** Nektar Therapeutics ([NASDAQ: NKTR](#))
 - **What:** Securities fraud class action lawsuit filed
 - **Class Period:** February 26, 2025 through December 15, 2025
 - **Deadline to Seek Lead Plaintiff Status:** May 5, 2026
 - **Key Lawsuit Allegations:** Material misstatements and/or omissions concerning the company's lead product candidates trial
 - **Investor Action:** Contact [Kessler Topaz Meltzer & Check, LLP \(www.ktmc.com\)](http://www.ktmc.com) for recovery options
-

The *Nektar Therapeutics* class action lawsuit was filed on behalf of those who purchased or otherwise acquired *Nektar Therapeutics* ("*Nektar*") (NASDAQ: NKTR) securities between February 26, 2025 and December 15, 2025, inclusive (the "Class Period"). Captioned *Schramke v. Nektar Therapeutics*, No. 26-cv-01951 (N.D. Cal.), the *Nektar* class action lawsuit alleges that *Nektar* and/or certain of its officers and/or directors violated federal securities laws by making false or misleading statements and/or omitted to disclose material information.

If you lost money as a result of your *Nektar* investment and want to find out more about this action and your rights, fill out the form on this page or contact attorney Jonathan Najj, Esq. of KTMC by calling (484) 270-1453 or via e-mail at info@ktmc.com. Lead plaintiff motions must be filed with the court no later than May 5, 2026.

COMPLAINT ALLEGATION SUMMARY:

Nektar is a biopharmaceutical company focused on the development of therapies to treat autoimmune disorders. Its lead product candidate is rezpegaldesleukin, which is a novel regulatory T-cell simulator for the treatment of alopecia areata. The Phase 2b trial for rezpegaldesleukin was initiated in March of 2024, and was designed to evaluate patients with severe to very severe alopecia areata that had not previously been treated with a Janus kinase inhibitor or other biologics. By February 2025, *Nektar* announced that its target enrollment had been met for the trial.

The complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material facts about the company's business, operations, and prospects. Specifically, Defendants misrepresented and/or failed to disclose that: (1) enrollment in the trial did not follow applicable instructions and protocols; (2) by not following standard protocols, the trials integrity and prospects had been compromised and would likely have a significant negative impact on its results; and (3) as a result of the foregoing, Defendants' statements about the

company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

WHY DID NEKTAR'S STOCK DROP?

On December 16, 2025, *Nektar* announced that the trial failed to reach statistical significance, largely due to the participation of four patients that should not have been deemed eligible to take part in the trial. On this news, *Nektar's* stock fell 7.77%.

THE LEAD PLAINTIFF PROCESS:

The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired *Nektar* securities during the Class Period to seek appointment as lead plaintiff in the *Nektar* class action lawsuit. A lead plaintiff is a representative party that acts on behalf of other class members in directing the litigation. In order to be appointed lead plaintiff, the Court must determine that the class member's claim is typical of the claims of other class members, and that the class member will adequately represent the class. Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. Filling out the online form above or communicating with any counsel is not necessary to participate or share in any recovery achieved in this case. Any member of the purported class may move the court to serve as a lead plaintiff through counsel of his/her choice, or may choose to do nothing and remain an inactive class member.

ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP:

Kessler Topaz Meltzer & Check, LLP (KTMC) is a leading U.S. plaintiff-side law firm focused on securities-fraud class actions and global investor protection. The firm represents individual investors as well as institutions, such as major pension funds, asset managers, and international investors. KTMC has led some of the largest recoveries in securities litigation and has been recognized by peers and the legal media with numerous accolades, including The National Law Journal's Plaintiff's Hot List and Trailblazers in Plaintiffs' Law, BTI Consulting Group's Honor Roll of Most Feared Law Firms, The Legal Intelligencer's Class Action Firm of the Year, Lawdragon's Leading Plaintiff Financial Lawyers, and Law360's Titans of the Plaintiffs Bar. The firm operates globally with offices in Pennsylvania and California. KTMC has recovered over \$25 billion for our clients and the classes they represent.

